AAREYDRUGS vs SANOFI: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Sanofi India Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Sanofi India Limited is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows faster revenue growth, while Sanofi India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Sanofi India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 1 of 13 scored metrics and SANOFI on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SANOFI is the larger company
₹7,850 Cr vs ₹221 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 55.36x
P/B Ratio
SANOFI has a lower P/B
0x vs 1.46x
EPS
SANOFI has higher earnings per share
₹134.59 vs ₹1.47
Dividend Yield
SANOFI has a higher dividend yield
7.15% vs 0%
Revenue Growth (TTM YoY)
AAREYDRUGS has faster revenue growth
19.8% vs -11.9%
EPS Growth (TTM YoY)
SANOFI has faster EPS growth
-14.1% vs -41.05%
Qtr Sales Growth
SANOFI has stronger quarterly sales growth
9.74% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSSANOFI
Live Price₹90.51₹3,412
Day Change-4.92%0.85%
Volume2.2 L13,274
52-Week High₹96₹5,955
52-Week Low₹50.31₹3,054
Distance from 52W High-5.72%-42.7%

Valuation

MetricAAREYDRUGSSANOFI
Market Cap₹221 Cr₹7,850 Cr
P/E Ratio55.36x0x
P/B Ratio1.46x0x
EPS₹1.47₹134.59
Book Value₹48.67₹325.31
Dividend Yield0%7.15%

Growth

MetricAAREYDRUGSSANOFI
Revenue Growth (TTM YoY)19.8%-11.9%
EPS Growth (TTM YoY)-41.05%-14.1%
Qtr Sales Growth0%9.74%
Qtr Profit Growth0%22.4%

Profitability & Leverage

MetricAAREYDRUGSSANOFI
ROE2.64%47.1%
ROCE6%49.2%
Net Margin0.84%19.26%
Operating Margin2.21%24.4%
Debt to Equity0.33x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSSANOFI
Promoter Holding37.71% 1.35 pp0%
FII Holding4.18% 0.32 pp5.64% 0.09 pp
DII Holding1.62% 1.62 pp21.13% 0.18 pp
Public Holding56.49% 0.6 pp12.83% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Sanofi India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.